Immune agonists show promising efficacy in solid tumor indications. However, dose-limiting toxicity liabilities due to on-target off-tumor binding limit their efficacy. Mabimmune’s Reverse Translational Medicine (RTM) human monoclonal antibodies bind neo-epitopes unique the tumor microenvironment but not other tissues. Generated in humans and cloned directly from human genes, RTM antibodies have fully human germline sequences and thereby offer the lowest toxicity, off-tumor sinking, and immunogenicity risk of any other antibody class. Mabimmune is developing immune agonists from the RTM platform designed to offer best-in-class therapeutic indices.